Initial German Purchase Orders and Import Permits
| Stock | Bioxyne Ltd (BXN.ASX) |
|---|---|
| Release Time | 15 Sep 2025, 9:05 a.m. |
| Price Sensitive | Yes |
Bioxyne Receives Initial German Purchase Orders and Import Permits
- Bioxyne secures import authorizations from German government for 1,550kg of medical cannabis
- Received A$5.1m in purchase orders from German clients, with exports planned for late September/early October
- Forecasted reorders from German clients expected to exceed the A$5.6m contracted in June 2025
Bioxyne Limited (ASX: BXN) has announced that it has received import authorizations from the German government for 1,550kg of medical cannabis products. This follows the company's announcement on 18 June 2025 that it had entered the German cannabis market, executing a commercial agreement to supply a minimum of A$5.6m of GMP medical cannabis flower product manufactured by its subsidiary, Breathe Life Sciences (BLS), in Australia in FY2026. As of 10 September 2025, the company has received purchase orders from its German clients for A$5.1m, with export to Germany planned for the end of September/early October. Farmakem and Adrex, Bioxyne's German clients, have forecasted reorders in November, January, March, and May, subject to import/export permitting and local market conditions. The forecasted reorders are expected to exceed the A$5.6m contracted under the June 2025 Supply Agreement.
Bioxyne has received A$5.1m in purchase orders from German clients, with exports planned for late September/early October. Forecasted reorders are expected to exceed the A$5.6m contracted in June 2025 for the FY2026 period.
Bioxyne expects to continue receiving reorders from its German clients, subject to import/export permitting and local market conditions, with the forecasted reorders expected to exceed the A$5.6m contracted in June 2025.